Exchange Surveillance
No active ASM or GSM measures on this stock.
Price band ± 5% · narrower than the standard 20%
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Medicamen Biotech Limited is engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. It is a manufacturer and supplier of a range of products, such as tablets, capsules, liquid syrup and dry syrup (beta lactum and non beta lactum), and ointment. Its product offerings include Acarbrose Tablets 50 milligram, Acetazolamide Tablet 250 milligram BP, Amitriptyline Hcl Tablet 25 milligram, Amlodipine Besylate Tablet 10 milligram, and Sulfadoxine and Anti Malarial Kit. As of March 31, 2012, its production capacity under beta lactum included tablets (eight million per day), capsules (one million per day), oral liquid (4600 liters per day), and dry syrup (6000 kilogram per day). Its production capacity under non beta lactum included tablets (one million per day), capsules (one million per day), liquid (1300 liters per day), and dry syrup (50,000 bottles per day). The Company has two manufacturing at Bhiwadi and Haridwar.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- New Delhi, Delhi
- Chairman
- Rahul Bishnoi
- Registrar
- Link Intime India Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE646B01010
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Medicamen Biotech Ltd today?
Medicamen Biotech Ltd (MEDICAMEQ) is trading at ₹253.35. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is MEDICAMEQ’s P/E ratio versus the sector?
MEDICAMEQ trades at a P/E of 42.1. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is MEDICAMEQ’s dividend yield?
MEDICAMEQ has a dividend yield of 0.31%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is MEDICAMEQ’s 52-week high and low?
MEDICAMEQ has traded between ₹212.4 and ₹447.65 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Medicamen Biotech Ltd?
Medicamen Biotech Ltd has a market capitalisation of ₹433 crore.
▶What is MEDICAMEQ’s return on equity?
MEDICAMEQ reports a return on equity of 3.8%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are MEDICAMEQ’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is MEDICAMEQ’s promoter holding?
Promoters hold 40.46% of MEDICAMEQ. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include MEDICAMEQ?
Index membership is listed in the Context block on this page, along with the weight MEDICAMEQ carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Medicamen Biotech Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from MEDICAMEQ’s own numbers. The judgement is yours.
MEDICAMEQ at a glance
Medicamen Biotech Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Medicamen Biotech Ltd (MEDICAMEQ) last traded at ₹253.35, giving it a market capitalisation of ₹433 crore. The 52-week range is ₹212.4 to ₹447.65, and the price is 17% of the way up that range. It trades at a price-to-earnings ratio of 42.1. Promoters hold 40.46% of the company in the latest shareholding filing.
| Market cap | ₹433 crore |
|---|---|
| P/E | 42.1 |
| ROE | 3.8% |
| ROCE | 5.5% |